IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2994 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
 
REVIEW ARTICLE
Ahead of Print

Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population


1 Division of Rheumatology, Allergy and Clinical Immunology, Davis, CA, USA
2 Department of Dermatology, KPC Medical College, Kolkata, West Bengal, India
3 Department of Dermatology, School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea; Department of Dermatology, School of Medicine, University of California, Davis, CA, USA
4 VA Medical Center Sacramento, Mather, CA, USA
5 Department of Critical Care Medicine, IPGME and R, Kolkata, West Bengal, India
6 Division of Rheumatology, Allergy and Clinical Immunology; Department of Dermatology, School of Medicine, University of California, Davis; VA Medical Center Sacramento, Mather, CA, USA

Correspondence Address:
Siba P Raychaudhuri,
Department of Medicine and Dermatology, Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California Davis, Davis, CA; VA Medical Center Sacramento, 10535 Hospital Way, Bldg #650, Research Service, Mather, CA 95655
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdvl.IJDVL_791_18

PMID: 31719235

Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis. However, a major concern is that patients receiving this therapy have an increased risk of infection, particularly of reactivation of latent tuberculosis (TB). There were an estimated 10.4 million new cases of tuberculosis in 2016, worldwide, and India has one of the largest TB case burden with an estimated incidence of 2.79 million cases of TB in the same year. Anti-TNF agents like etanercept and infliximab are available in India approved for psoriasis and psoriatic arthritis. But long-term use of these agents possesses a risk of reactivation of latent TB. In this review article, we assessed the risk of TB with anti-TNF therapy especially in patients with psoriasis and psoriatic arthritis in India. At the end of the article, we have also suggested a recommendation for screening of latent tuberculosis and its management, before starting anti-TNF-α therapy.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Sarkar S
    -  Panda S
    -  Kim B
    -  Raychaudhuri SK
    -  Ghosh A
    -  Raychaudhuri SP
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed219    
    PDF Downloaded18    

Recommend this journal

Online since 15th March '04
Published by Wolters Kluwer - Medknow